Latest News

Use of SBRT Improves OS Rates Among Veterans With Stage I NSCLC

Use of SBRT Improves OS Rates Among Veterans With Stage I NSCLC

The adoption of stereotactic body radiation therapy (SBRT) is associated with substantial improvements in overall and lung cancer-specific survival rates.

Tumor-specific Biomarkers Predict Response in HER-2-positive Breast Cancer

Tumor-specific Biomarkers Predict Response in HER-2-positive Breast Cancer

Human epidermal growth factor receptor 2 (HER-2) breast cancers are genetically heterogeneous.

Survival Rate Rising Among Elderly Patients With NSCLC Treated With SBRT

Survival Rate Rising Among Elderly Patients With NSCLC Treated With SBRT

Increase in the survival rate for elderly non-small cell lung cancer (NSCLC) attributed to increased use of stereotactic body radiation therapy (SBRT).

Encorafenib + Binimetinib Improves PFS Versus Vemurafenib Alone in Melanoma

Encorafenib + Binimetinib Improves PFS Versus Vemurafenib Alone in Melanoma

Encorafenib plus binimetinib significantly improved progression-free survival in melanoma.

Carfilzomib + Melphalan, Prednisone Fails to Improve PFS in Myeloma

Carfilzomib + Melphalan, Prednisone Fails to Improve PFS in Myeloma

Adding carfilzomib to melphalan and prednisone (KMP) is not superior to bortezomib, melphalan, prednisone (VMP) for improving progression-free survival.

Combination Therapy May Improve Survival in Nasopharyngeal Carcinoma

Combination Therapy May Improve Survival in Nasopharyngeal Carcinoma

Induction chemotherapy with concurrent chemoradiotherapy may improve survival of patients with nasopharyngeal cancer.

No Difference in PFS Between RT and Temozolomide in Glioma

No Difference in PFS Between RT and Temozolomide in Glioma

Patients with low-grade glioma have no significant difference in progression-free survival when treated with either radiotherapy alone or temozolomide chemotherapy alone.

PSA Testing Unchanged in Years After USPSTF Recommendation

PSA Testing Unchanged in Years After USPSTF Recommendation

Prostate-specific antigen (PSA) testing behavior did not significantly change in the years after a USPSTF recommendation against PSA screening.

Risk of Arrhythmias, Bleeding Higher With Ibrutinib Therapy

Risk of Arrhythmias, Bleeding Higher With Ibrutinib Therapy

Ibrutinib therapy carries a significantly higher risk of atrial fibrillation/flutter and all-grade bleeding compared with other treatments.

MRI May Be Effective Screening Test for Hepatocellular Carcinoma

MRI May Be Effective Screening Test for Hepatocellular Carcinoma

Magnetic resonance imaging (MRI) may be an effective tool for diagnosing hepatocellular carcinoma (HCC).

Prolonged Imatinib Therapy Linked With Deeper Molecular Response in CML-CP

Prolonged Imatinib Therapy Linked With Deeper Molecular Response in CML-CP

For patients with chronic myeloid leukemia, prolonged imatinib use helps achieve deeper molecular response with long-term treatment.

Study Emphasizes Importance of Skin Exams for Organ Transplant Recipients

Study Emphasizes Importance of Skin Exams for Organ Transplant Recipients

Nonwhite organ transplant recipients are at risk for developing non-melanoma skin cancer following transplantation.

TP53, MDM2 Alterations Linked to Cisplatin Resistance in Testicular Cancer

TP53, MDM2 Alterations Linked to Cisplatin Resistance in Testicular Cancer

TP53 and MDM2 alterations are associated with resistance to cisplatin and inferior progression-free survival among patients with metastatic germ cell tumors.

Alpha-fetoprotein Levels May Predict HCC Response to Ramucirumab

Alpha-fetoprotein Levels May Predict HCC Response to Ramucirumab

Alpha-fetoprotein (aFP) levels of at least 400 ng/mL predict patients with hepatocellular carcinoma (HCC) likely to respond to second-line ramucirumab.

Post-mastectomy Radiotherapy Reduces Risk for Locoregional Failure, Recurrence

Post-mastectomy Radiotherapy Reduces Risk for Locoregional Failure, Recurrence

Treatment with post-mastectomy radiotherapy (PMRT) reduces the risk for locoregional failure (LRF) recurrence and mortality.

Circulating Plasma Cells Predict Poor Prognosis in Multiple Myeloma

Circulating Plasma Cells Predict Poor Prognosis in Multiple Myeloma

The presence of circulating plasma cells (CPCs) predicts a worse prognosis for patients with multiple myeloma.

Response Rate Similar Between Low- and Standard-dose Ponatinib

Response Rate Similar Between Low- and Standard-dose Ponatinib

Response with low-dose ponatinib is similar to that of standard-dose ponatinib among patients with refractory chronic myeloid leukemia (CML).

Imatinib Less Beneficial for Patients With CML in Accelerated Phase

Imatinib Less Beneficial for Patients With CML in Accelerated Phase

Patients with chronic myeloid leukemia (CML) in accelerated phase may obtain less clinical benefit with first-line imatinib therapy.

Ibrutinib Linked With Favorable Survival, High Response Rate in CLL

Ibrutinib Linked With Favorable Survival, High Response Rate in CLL

Treatment with ibrutinib may be associated with favorable progression-free and overall survival as well as high overall response rate.

FDA Accepts NDA for Neratinib in HER2+ Early Stage Breast Cancer

FDA Accepts NDA for Neratinib in HER2+ Early Stage Breast Cancer

The FDA accepted a New Drug Application for neratinib for the extended treatment of patients with early HER2-positive breast cancer.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters